Larimar Therapeutics (LRMR) Gains from Investment Securities: 2015-2020
Historic Gains from Investment Securities for Larimar Therapeutics (LRMR) over the last 2 years, with Mar 2020 value amounting to $6.8 million.
- Larimar Therapeutics' Gains from Investment Securities rose 242.04% to $6.8 million in Q1 2020 from the same period last year, while for Mar 2020 it was $6.8 million, marking a year-over-year increase of 242.04%. This contributed to the annual value of $465,000 for FY2024, which is 41.14% down from last year.
- As of Q1 2020, Larimar Therapeutics' Gains from Investment Securities stood at $6.8 million, which was up 9,748.66% from $69,000 recorded in Q3 2019.
- Larimar Therapeutics' 5-year Gains from Investment Securities high stood at $6.8 million for Q1 2020, and its period low was $69,000 during Q3 2019.
- Over the past 3 years, Larimar Therapeutics' median Gains from Investment Securities value was $2.0 million (recorded in 2019), while the average stood at $2.8 million.
- As far as peak fluctuations go, Larimar Therapeutics' Gains from Investment Securities soared by 313.57% in 2018, and later crashed by 96.95% in 2019.
- Quarterly analysis of 5 years shows Larimar Therapeutics' Gains from Investment Securities stood at $1.5 million in 2016, then declined by 20.47% to $1.2 million in 2017, then surged by 313.57% to $5.0 million in 2018, then slumped by 96.95% to $69,000 in 2019, then spiked by 242.04% to $6.8 million in 2020.
- Its Gains from Investment Securities was $6.8 million in Q1 2020, compared to $69,000 in Q3 2019 and $2.0 million in Q1 2019.